Introduction: Angiotensin-converting enzyme inhibitors (ACEIs) are among the most frequently prescribed medications used to treat hypertension and are commonplace among patients undergoing elective total hip and knee arthroplasty. It is the purpose of this study to evaluate the perioperative effects of ACE-Is in an elective total hip and knee arthroplasty patient group.
INTRODUCTION
Angiotensin-converting enzyme inhibitors are among the most frequently prescribed medications used to treat hypertension and are commonplace among patients undergoing elective total hip and knee arthroplasty. 1 Perioperative practices regarding cessation of ACE-Is are varied; it is sometimes recommended to have patients stop taking their ACE-I 1 or 2 days prior to the day of surgery.
Total hip and knee arthroplasty can be classified as major elective surgery, and as such, patients undergo fluid shifts within the body around the time of surgery. Frequently, patients are hypotensive both intraoperatively and postoperatively, and up to 18% of patients have been reported to suffer AKI around the time of total joint arthroplasty. [2] [3] [4] [5] Postoperatively, hypotensive events may also cause patient discomfort in the form of lightheadedness; dizziness and nausea and can result in the withholding of pain medications, leading to increased pain. Some have postulated that the continued use of an ACE-I preoperatively, specifically on the same day of surgery, predisposes patients to both intraoperative and postoperative hypotensive events.
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Conversely, several authors have reported that in conjunction with general anesthetics, renin-angiotensin system (RAS)-blockading agents either do not effect, or improve, cardiovascular stability in the perioperative period. [12] [13] [14] Stress to the body, including surgery and hypotension, stimulates the generation of angiotensin II. 15 Angiotensin II induces vasoconstriction to maintain blood pressure but simultaneously reduces blood flow to organs including the kidneys and intestine. 15 This angiotensin II-induced reduction in blood flow may contribute to postoperative morbidity in the form of AKI and/or splanchnic ischemia. [16] [17] [18] In turn, blockade of the RAS with ACE inhibitors may have some protective value with regard to circulation in these regions of the body 13, 19, 20 and has led some to recommend uninterrupted continuation of these medications during the preoperative period, particularly in certain high-risk patients. 1, 21 There are also concerns regarding postoperative hypertension when ACE-Is are discontinued preoperatively. In a randomized controlled trial by Pigott et al, 22 the effects of continuing vs discontinuing ACE-Is in cardiac surgery patients were investigated and they found no difference in intraoperative hypotension, but a higher rate of postoperative hypertension that required vasodilator administration in those who discontinued ACE-Is. Despite numerous small studies in the general surgery literature investigating the issue, there is no evidence-based consensus regarding the pros and cons of continuing ACE-I and angiotensin receptor blocker (ARB) therapy during the perioperative period. This uncertainty stems from a lack of randomized controlled trials designed to examine differences between outcomes in patients treated with continuation or cessation of ACEIs, especially in the joint arthroplasty literature. It was the purpose of this study to evaluate the perioperative effects of ACE-Is in an elective total hip and knee patient group. A better understanding of the consequences of withholding or continuing these medications in the perioperative period will enhance the care of patients electing to undergo total joint arthroplasty. We hypothesized that there would be no difference in intraoperative and postoperative outcomes between patients who withheld or continued their prescribed ACE-I preoperatively.
MATERIALS AND METHODS
This study was approved by the appropriate institutional review board. Adult patients aged 18 years and over electing to undergo primary or revision total hip or knee arthroplasty and currently taking an ACE-I were asked to participate in this study. Exclusion criteria for this study included trauma patients, immunosuppressed patients (human immunodeficiency virus/acquired immunodeficiency syndrome, chronic steroid use, on chemotherapy, or history of organ transplant), patients with history of severe hypertension-related illness (such as hypertension-associated stroke or myocardial infarction), and patients in whom continuation of their ACE-I was expressly mandated by their prescribing physician. Informed consent was obtained from all participants. Total hip or knee arthroplasty was performed as per the standard of care as determined by the patient, attending surgeon, and attending anesthesiologist. No alterations of the surgical procedure or anesthesia were performed as a result of the proposed study.
Patients were randomized to one of two study arms, including cessation and continuation. A randomization scheme was generated for a single site using a block size of 4 to balance treatment arms 1:1. At the time of consent, patients were randomized to one of the two study arms. Patients in the cessation arm were instructed to stop their ACE-I 2 days prior to surgery (last dose >48 hours prior to surgery). Patients in the continuation arm continued their ACE-I and took their scheduled dose on the day of surgery. Demographics of each patient, including age, gender, race, type of total joint arthroplasty (hip or knee), and anesthesia type were recorded.
Patients were tracked in the perioperative period. Instances of both mild (systolic <85 mm Hg) and severe hypotension (<65 mm Hg systolic) were recorded. Both intraoperative and postoperative use of vasopressors was also recorded, as well as median hospital length of stay and instance of acute kidney insufficiency, as measured by an increase in creatinine of 0.3 or greater from baseline. In addition, we recorded the requirement of escalation of care requiring transfer to a step-down unit or intensive care unit (ICU), and the use of allogeneic blood.
Continuous data are presented using the mean, standard deviation, median, or range based on distribution of variable, and categorical data are summarized using counts with percentages. Comparisons between treatment arms utilized the t-test or Wilcoxon rank sum test for continuous variables and chi-square or Fisher's exact test for categorical data (expected cell counts < 5). Analyses were performed by the Duke Department of Biostatistics (Durham, NC) using SAS version 9.4 (SAS, Inc., Cary, NC). All statistical tests were two-sided superiority tests and a p-value < 0.05 was considered statistically significant.
RESULTS
A total of 59 people met criteria and agreed to participate in the study. Of those, 6 were lost to follow-up, 3 did not undergo total joint surgery, 2 subjects withdrew their participation prior to scheduled surgery, and 2 subjects were withdrawn by the study team due to perioperative deviations from surgery protocol (One patient underwent unicompartmental knee arthroplasty and one patient was randomized to continuation arm but was instructed to stop ACE-I by anesthesia team). Data were analyzed from the remaining 46 participants, of which 23 had been randomized to the continuation arm, and 23 randomized to the cessation arm. Demographics of each group are shown in Table 1 .
Despite being underpowered to detect significant differences between cessation and continuation arms of the study, the continuation arm had more intraoperative hypotension (61 vs 39%, p = 0.140), more intraoperative DOJ vasopressors (83 vs 61%, p = 0.102), more postoperative hypotension (13 vs 9%, p = 1.000), and more AKI (22 vs 14%, p = 0.700). Further, in the continuation arm, 1 patient sustained severe intraoperative hypotension and required postoperative escalation of care requiring transfer of care to a step-down unit or the ICU. This same patient also required the use of allogeneic blood. In the cessation arm, no patients sustained severe intraoperative hypotension, required transfer of care to a step-down unit or the ICU, or required the use of allogeneic blood. Due to the low number of these rare events occurring, statistical comparative analysis was not performed (Table 2) .
DISCUSSION
The results of this randomized controlled trial did not show a statistical difference between treatment groups but did show a trend toward worse outcomes in total joint arthroplasty patients who continued ACE-Is through the perioperative period. Based on intraoperative hypotension rates observed in each arm, we would need at least 82 subjects randomized per arm to have at least 80% statistical power to show a significant difference using a two-sided Z-test with pooled variance and significance level of 0.05. Measured outcomes included intraoperative hypotension, use of vasopressors, postoperative hypotension, hospital stay, and incidence of AKI. Despite being underpowered to detect a significant difference between cessation and continuation arms of the study, the continuation arm had more intraoperative hypotension (61 vs 39%, p = 0.140), more intraoperative vasopressors (83 vs 61%, p = 0.102), more postoperative hypotension (13 vs 9%, p = 1.000), and more AKI (22 vs 14%, p = 0.700). Further, a patient in the continuation arm sustained severe intraoperative hypotension, requiring postoperative escalation of care and allogeneic blood transfusion.
Patients undergoing elective total joint procedures often have preoperative appointments with their primary care physicians and anesthesiologists where they are given strict instructions regarding us of their home medication on the day of surgery. Antihypertensive medications, including ACE-Is, are sometimes held on the day of elective total hip or knee arthroplasty with the intent of minimizing complications in the perioperative period. However, conflicting data exist for the recommendation of discontinuing antihypertensives prior to surgery, [5] [6] [7] [8] [9] [10] [11] and uncertainty remains as to whether or not continuing ACEIs in the preoperative period leads to intraoperative and postoperative complications. The findings of the current study have prompted the authors to advise caution when continuing ACE-Is in the elective total joint arthroplasty perioperative period. The cause of perioperative hypotension is no doubt multifactorial with factors including the specific type of anesthesia administered, dehydration from preoperative fasting, and the patient's routine use of antihypertensives. Colson et al 7 reported on the hemodynamic effects of anesthesia in patients chronically treated with ACE-Is. They found that in these patients with intraoperative hypotension, they were able to attain rapid restoration of arterial BP with IV fluids and occasional vasopressors, and in addition, found that this did not lead to postoperative complications. In the current study, we found that intraoperative hypotensive events associated with the continuation of ACE-Is may not be so benign and may even require escalation of care or blood transfusion. Again, a limitation of this study is low statistical power, as we assessed a relatively small number of participants. In addition, this study excluded patients with a history of severe hypertension-related illness, such as stroke and myocardial infarction, who may be more prone to significant hypotension after induction of general anesthesia with continuation of ACE-Is or ARBs on the morning of surgery. 23 Further retrospective studies are recommended to determine if a patient's prior medical history, particularly those of cardiac and cerebrovascular events, or preoperative hydration status, may prove to be a better indicator of possible postoperative hypotensive events. Although this study was limited by its statistical power, we would recommend against other prospective studies comparing continuation vs cessation of ACE-Is on the day of elective arthroplasty surgery as the trend toward worse outcomes with continuation of ACE-Is appears to be real and dangerous.
CONCLUSION
When comparing patients in a select population who continued ACE-Is on the day of total hip or knee arthroplasty with those who ceased taking their ACE-I 2 days prior to surgery, there was a trend toward worse outcomes in those that continued ACE-Is. We recommend that caution be taken when continuing ACE-Is in the elective total joint arthroplasty perioperative period.
